Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating

Moomoo NewsJan 15 02:31 ET · Ratings

ADMA Reports 2024 Preliminary Revenue Of $ $417M-425M ($422.39M Est.) With With Over $100M Cash, Projects FY 2025 Revenue Over $485M And FY 2026 Above $600M

BenzingaJan 13 07:09 ET

Express News | ADMA Biologics Inc FY2025 Rev View $484.5 Mln -- LSEG IBES Data

ReutersJan 13 07:02 ET

Press Release: ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update

Dow JonesJan 13 07:00 ET

ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update

ADMA BiologicsJan 13 00:00 ET

ADMA Stock Catapults 275.7% in a Year: How Should You Play the Stock?

Zacks Jan 10 13:00 ET